Table 3.

List of all patients treated with Sirolimus

Patient	Sex	Age at first recurrence (years)	Initial tumor site	Molecular subgroup	Recurrence number at Sirolimus application	Combination partner(s)	Resection at same recurrence	Radiation at same recurrence	Best response	Time to progression (months)
Evaluable responses
1	Male	3.4	Infratentorial	NA	4	+ Imatinib, Topotecan, Temozolomide	NTR	No	PD	1.3
2	Male	3.6	Infratentorial	PF-A	2	+ Dasatinib, Irinotecan, Temozolomide	NTR	Yes	SD	15.3
3	Male	3.1	Infratentorial	PF-A	3	–	No resection	Yes	SD	24.0
4	Female	8.9	Infratentorial	NA	3	+ Dasatinib, Irinotecan, Temozolomide	STR	Yes	PD	4.9
5	Male	10.1	Infratentorial	PF-A	3	–	No resection	Yes	PD	13.5
					4	–	STR	No	PD	2.3
6	Female	2.8	Infratentorial	PF-A	2	+ Dasatinib, Irinotecan, Temozolomide	No resection	Yes	SD	13.5
7	Male	0.9	Infratentorial	ZFTA	3	–	No resection	Yes	SD	15.6
Applications after surgery without evaluable rest-tumor
7	Male	0.9	Infratentorial	ZFTA	4	–	GTR	No	n.e	40.2+
8	Male	4.5	Infratentorial	PF-A	1	+ Sunitinib, Irinotecan, Temozolomide	GTR	No	n.e	5.8
9	Male	3.3	Infratentorial	PF-A	1	–	GTR	Yes	n.e	53.6

Best response could only be evaluated if previous to response measurement no surgery was performed or enough rest-tumor was present after surgery to measure the response to the applied chemotherapy

GTR gross-total resection, NTR near-total resection, STR sub-total resection, SD stable disease, PD progressive disease, n.e. not evaluable

 + indicates ongoing response at last follow-up